1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   Response -  Analytic Code
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [abhi.chhabra796@gmail.com].
   


6. For how long will this data be available start date provided 10-01-2026 and end date provided 10-01-2031?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Ureteral stents are now very commonly used in various urological disorders Ureteral stents are frequently used to relieve obstruction of urinary tract to secure ureteral anastomoses and to provide effective drainage of upper urinary tract after various urological interventions. The term stent-related symptoms SRS refers to a broad range of symptoms in the early postoperative phase include transient fever hematuria frequency urgency and pain in the flank and or suprapubic area

The symptoms associated with a DJ stent can present clinically like an overactive bladder and are mediated by cholinergic and alpha adrenergic receptors The three main pharmacological types that have been studied over the past few decades and found out to be beneficial in reducing stent associated symptoms are beta 3 agonists alpha blockers and anticholinergics

Tamsulosin and silodosinin are specific alpha1a inhibitors that inhibit the contraction of the lower ureter bladder neck and bladder trigone muscles hence reducing pain and discomfort associated with the lower urinary tract

 The only selective beta 3 adrenergic agonist available for treating overactive bladder is mirabegron. It works by reducing patients’ irritation in the bladder when they have a ureteral stent in situ

Ureteral Stent Symptom Questionnaire USSQ is a questionnaire which is self administered and assesses aspects of stent related symptoms Patients will be randomized into two groups 1 to 1 by a computer generated randomization

Group A patients will be given tamsulosin 04 mg and solifencain 10 mg combination once daily Group B patients will be given Silodosin 8 mg and Mirabegron 50 mg combination once daily All patients are to be followed up for 6 weeks from double J stent placement Comparisons of clinical demographic and intraoperative findings will be done and patients will be followed up in terms of symptoms using USSQ score at 1 week post procedure 3 and 6 weeks post procedure